Financial Performance - Revenue for 2022 reached RMB 7,151,039, an increase of 12.4% compared to RMB 6,359,786 in 2021[6] - Profit before tax for 2022 was RMB 829,851, representing a 273.5% increase from RMB 222,264 in 2021[6] - Profit attributable to owners of the Company for the year was RMB 727,077, up from RMB 240,788 in 2021, marking a significant increase of 202.5%[6] - For the year ended December 31, 2022, the Group achieved operating revenue of RMB 7,151 million, representing an increase of 12.4% compared to the previous year[11] - The gross profit margin for the year was 32.0%, an increase of 0.7 percentage points from the previous year[11] - Profit attributable to owners of the Company amounted to RMB 727.1 million, reflecting a year-on-year growth of 202.0%[12] - The sales of finished dose pharmaceutical products increased by 21.7% to RMB 3,210.5 million, while API sales decreased by 1.8% to RMB 2,673.8 million[27] - The CDMO service segment saw a significant growth of 33.3%, with operating income reaching RMB 1,084.1 million[27] - The Group's gross profit margin improved compared to the previous year, indicating better cost control and operational efficiency[24] - The Group's financial summary for the last five financial years is available on page 5 of the annual report[84] Assets and Liabilities - Total assets as of 2022 amounted to RMB 20,814,204, an increase from RMB 19,108,177 in 2021[7] - Total liabilities increased to RMB 8,406,565 in 2022, compared to RMB 7,584,862 in 2021[7] - Equity attributable to shareholders of the Company was RMB 12,310,915 in 2022, up from RMB 11,411,354 in 2021[7] - The asset-liability ratio was approximately 40.4% as of December 31, 2022, compared to approximately 39.7% as of December 31, 2021[55] - The Group's interest-bearing borrowings amounted to approximately RMB 6,317.5 million as of December 31, 2022, up from approximately RMB 5,518.4 million as of December 31, 2021[62] Market Expansion and Strategy - The Company plans to expand its market presence and invest in new product development in the upcoming year[6] - The management highlighted ongoing research and development efforts aimed at enhancing product offerings and technological advancements[6] - The Company is exploring potential mergers and acquisitions to strengthen its market position and drive growth[6] - Hepalink aims to enhance its digitalization capabilities and build an integrated production and sales model to improve operational efficiency and reduce costs[15] - The Group plans to strengthen its supply chain management to effectively control procurement costs and improve profit margins[15] - The Company is committed to becoming a leading innovative multinational pharmaceutical company globally by strengthening its core competencies[15] Sales and Distribution - Global sales volume in 2022 exceeded 227 million units, up 22.3% year-on-year, while sales revenue increased by 12.4% compared to the same period last year[12] - The Company achieved sales expansion in over 30 provinces and cities in China and entered into drug procurement catalogs of various regions[12] - Sales in the U.S. market maintained steady growth, with the Group's enoxaparin sodium finished doses becoming a market leader, supported by contracts with the three largest distributors and major Group Purchasing Organizations[30] - Sales in the China market exceeded 13 million units, representing an increase of more than 50%, with successful expansion into over 30 provinces and cities nationwide[30] - The Group's enoxaparin sodium injection brand, Prolongin, became the first to achieve online sales cooperation with multiple internet platforms in China[30] Research and Development - Hepalink has obtained exclusive development and commercial interest in Greater China for certain clinical stage innovative drug candidates targeting immune system diseases[17] - The global Phase III study of AR-301 enrolled 174 subjects, with 120 cases in the modified intention to treat (mITT) analysis, showing benefits for patients over 65 years old[37] - Oregovomab demonstrated a median progression-free survival (PFS) of 41.8 months in combination with chemotherapy, compared to 12.2 months for chemotherapy-only, with a hazard ratio (HR) of 0.46[37] - The critical technology R&D project for H1710 has been approved by the Science, Technology and Innovation Commission of Shenzhen[38] - The company is focused on innovative drug R&D, ensuring effective allocation and management of resources for clinical development[44] Corporate Governance - The Company aims to achieve good corporate governance standards to safeguard shareholder interests and enhance corporate value[149] - The Board comprises 6 Directors, including 3 executive Directors and 3 independent non-executive Directors[150] - The roles of Chairman and Chief Executive Officer are held by different individuals, ensuring compliance with governance standards[152] - The Company has received written annual confirmations of independence from all independent non-executive Directors, affirming their independence[152] - The Company has established a code of conduct for securities trading by its directors and senior management, ensuring compliance with required standards[149] Shareholder Engagement - The Company has established a shareholders' communication policy to ensure effective engagement with shareholders and regular reviews of its effectiveness[186] - The Board considers the implementation and effectiveness of the shareholders' communication policy to be sufficient and adequate during the reporting period[187] - The Company aims to maintain ongoing dialogue with shareholders through annual general meetings and other meetings[186] - The Group's largest customer accounted for 10.3% of total revenue, while the five largest customers contributed 31.7% of total revenue during the reporting period[140] Risk Management - The Company has established a robust internal control system to manage various potential risks related to its strategic plan, research and development, and other operational aspects[176] - The Board has reviewed the risk management and internal control systems and deemed them effective and adequate for the Reporting Period[177] - The Company has implemented measures to manage potential conflicts of interest between the Group and its Controlling Shareholders[176] - The Company faces risks related to market acceptance, pricing controls, and reimbursement policies that could adversely affect operations and profitability[146] Future Outlook - The global macroeconomic environment in 2023 is expected to be challenging, with China's economic rebound contrasting with recession risks in Europe and the U.S.[39] - The Company is optimistic about future prospects and will continue to implement its existing strategy while exploring new opportunities for business breakthroughs[45] - The management has set a revenue target of $500 million for the upcoming fiscal year, representing a 10% increase from the current year[64]

证券代码：002399 证券简称：海普瑞 公告编号：2023-027 深圳市海普瑞药业集团股份有限公司 关于举行2022年度网上业绩说明会的公告 一、业绩说明会召开时间及投资者参与方式 时间：2023年4月14日（星期五）下午15:00-16:30 召开方式：网络 参与方式：投资者可通过"同花顺路演平台"（http://board.10jqka.com.cn/rs/） 或同花顺App端入口（同花顺App首页-搜索-路演平台）参与本次年度业绩说明 会 二、公司出席人员 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 公司董事长李锂先生、董事兼总经理单宇先生、独立董事吕川先生、董事会 秘书钱风奇先生及财务总监向贤青先生。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）将于2023年4月 14日（星期五）通过"同花顺路演平台"举行2022年度业绩网上说明会，具体如 下： 三、问题征集 （问题征集专题页面二维码） 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 深圳市海普瑞药业集团股份有限公司 董事会 二〇二三年四月十二日 为充分尊重投资者、提升交流的针 ...

Dividend Distribution - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares to all shareholders, based on a total of 1,467,296,204 shares[4]. - The company distributed a cash dividend of 0.35 yuan per 10 shares based on a total share capital of 1,467,296,204 shares, approved at the 2021 annual general meeting[92]. - The cash dividend policy complies with the company's articles of association and has been transparently executed[93]. Financial Performance - The company reported a revenue of RMB 1.5 billion for the fiscal year 2022, representing a year-over-year growth of 15%[39]. - The company's total revenue for 2022 was RMB 7,159,410,684.41, primarily from the production and sales of heparin raw materials and formulations, as well as contract development and manufacturing organization (CDMO) services[113]. - The net profit for the year reached CNY 714,687,211.31, a significant increase compared to CNY 233,383,425.18 from the previous year, representing a growth of about 206.5%[191]. - The company's operating profit improved to CNY 828,623,184.85, up from CNY 227,474,697.78, marking an increase of around 264.5%[191]. - The company reported a decrease in accounts payable from CNY 171,477,883.69 to CNY 99,991,386.43, a reduction of about 41.7%[187]. - The total liabilities reached CNY 8,406.56 million, compared to CNY 7,584.86 million in the previous period, marking an increase of approximately 10.8%[183]. Future Guidance and Growth - The company has set a revenue guidance for 2023 at RMB 1.8 billion, indicating a projected growth of 20%[39]. - User data showed an increase in active users by 20% to 2 million in the same period[39]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[46]. - New product development includes a breakthrough in monoclonal antibody technology, expected to launch in Q3 2023[46]. Compliance and Governance - The company has maintained its commitment to transparency, with all financial reports signed and stamped by responsible parties[24]. - The company retained Ernst & Young Hua Ming as the domestic auditor for the 2022 financial report, with total audit fees amounting to RMB 5.58 million and internal control audit fees of RMB 0.43 million[54]. - The audit committee reviewed and agreed on the annual financial reports and internal control evaluations for 2021[153]. - The company has established a series of plans to ensure timely and full repayment of its bonds, including dedicated departments and personnel, and strict execution of financial management plans[88]. Employee and Management Information - The total number of employees at the end of the reporting period was 2,366, with 936 in the parent company and 1,430 in major subsidiaries[158]. - The company has established a competitive salary system based on performance and capability, ensuring fair compensation across different positions[158]. - Total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 1,396.48 million[176]. Risk Management - The company has detailed its future risks and countermeasures in the annual report, highlighting the importance of investor awareness regarding investment risks[19]. - The company has not reported any changes in its main business operations since its listing[32]. - The company has not reported any major matters that require explanation during the reporting period[65]. Financial Health Indicators - The company's EBITDA to total debt ratio improved to 21.40%, an increase of 8.47% compared to the previous year[106]. - The current ratio decreased by 1.14% to 2.222, while the quick ratio dropped by 21.39% to 0.9946[106]. - The debt-to-asset ratio increased to 40.39%, up by 0.70% from the previous year[106]. - Interest coverage ratio improved significantly to 4.53, a 115.71% increase from 2.10 in the previous year[130]. Asset and Liability Management - The total assets increased to CNY 14,483,308,913.97 from CNY 14,324,415,709.31, reflecting a growth of approximately 1.11%[187]. - Non-current liabilities totaled CNY 2,830.77 million, slightly up from CNY 2,793.39 million, indicating a growth of about 1.3%[183]. - The company's capital reserve decreased to CNY 5,858.62 million from CNY 5,943.65 million, a decline of about 1.4%[183]. Strategic Investments - The company has invested RMB 200 million in sustainable practices, aiming for a 30% reduction in waste emissions by 2025[46]. - The company has established partnerships with leading technology firms to enhance its production processes and product offerings[46]. - The company has made strategic investments in new product development and technology, although specific figures are not provided in the content[194].

Revenue and Profitability - Revenue increased by 12.4% to RMB 7,151.0 million (2021: RMB 6,359.8 million) [2] - Profit attributable to equity holders of the parent increased by RMB 486.3 million or 202.0% to RMB 727.1 million [2] - Net profit attributable to equity holders increased by 202.0% to RMB 727.1 million, with basic earnings per share rising to RMB 0.50 from RMB 0.16 in 2021 [11] - Gross profit was RMB 2,290.2 million (2021: RMB 1,993.6 million), with a gross margin of 32.0%, up 0.7 percentage points [2] - Gross profit increased by RMB 296.6 million to RMB 2,290.2 million, compared to RMB 1,993.6 million in the same period last year, with a gross margin rise from 31.3% to 32.0% [38] Business Segments Performance - Formulation business sales revenue grew by 21.7% to RMB 3,210.5 million (2021: RMB 2,638.2 million) [2] - CDMO business sales revenue increased by 33.3% to RMB 1,084.1 million (2021: RMB 813.1 million) [2] - The pharmaceutical formulation segment achieved a revenue growth of 21.7%, totaling approximately RMB 3,210.5 million, accounting for 44.9% of total revenue [15] - CDMO services revenue grew by 33.3% to RMB 1,084.1 million, indicating strong demand in this segment [13] - The API business generated approximately RMB 2,673.8 million in sales revenue, accounting for 37.4% of total revenue, with a gross margin improvement to 27.7% [19] Market Expansion and Strategy - The company has established exclusive development and commercialization rights for several innovative drug candidates in Greater China, focusing on immune-related diseases [10] - The supply chain strategy has been enhanced to ensure material supply and operational efficiency amid global economic challenges [10] - The company is actively developing proprietary drug candidates currently in the preclinical stage [10] - The company actively expanded its market presence in France and Switzerland, further solidifying its position in Europe [16] - The company achieved significant sales growth in emerging markets such as Malaysia, Brazil, and Saudi Arabia, while also advancing international drug registration efforts [17] Financial Position and Assets - Total assets less current liabilities amounted to RMB 15,238.4 million (2021: RMB 14,316.7 million) [7] - Net assets attributable to equity holders of the parent increased to RMB 12,310.9 million (2021: RMB 11,411.4 million) [7] - Total assets as of December 31, 2022, were approximately RMB 20,814.2 million, compared to RMB 19,108.2 million as of December 31, 2021 [46] - Total liabilities as of December 31, 2022, were approximately RMB 8,406.6 million, compared to RMB 7,584.9 million as of December 31, 2021, resulting in a debt-to-asset ratio of approximately 40.4% [46] Dividends and Shareholder Returns - The board declared a final cash dividend of RMB 1.0 per ordinary share (tax included) for the year [2] - The proposed final dividend per ordinary share for 2022 is RMB 0.10, compared to RMB 0.035 in 2021, representing an increase of 185.7% [77] - The final dividend will be distributed to H shareholders no later than August 15, 2023, if approved [87] - The annual general meeting is scheduled for May 22, 2023, where the dividend proposal will be discussed [88] Research and Development - The AR-301 monoclonal antibody is currently in global Phase III clinical trials, with 174 subjects enrolled, showing promising results in reducing mechanical ventilation time for patients with ventilator-associated pneumonia [24] - Oregovomab's Phase II clinical trial demonstrated a median progression-free survival (PFS) of 41.8 months compared to 12.2 months for the control group, with a hazard ratio (HR) of 0.46 [25] - RVX-208 has completed Phase III trials and received FDA breakthrough therapy designation, aiming to reduce major adverse cardiovascular events in high-risk patients [27] - H1710, an acetyl heparinase inhibitor, has completed active pharmaceutical ingredient production and is preparing for IND application in both China and the US [28] Operational Efficiency and Cost Management - The sales cost increased by RMB 494.7 million to RMB 4,860.9 million, primarily due to rising costs in pharmaceutical formulations and CDMO services [35] - Financing costs rose by RMB 35.5 million to RMB 245.6 million, an increase of 16.9% compared to RMB 210.1 million in the same period last year [39] - The company aims to enhance global supply chain management and digital integration to improve operational efficiency and resilience [29] Compliance and Governance - The audit committee reviewed the consolidated annual performance for the year ended December 31, 2022, and confirmed compliance with relevant accounting standards [92] - The company's auditor confirmed that the financial figures in the performance announcement are consistent with the consolidated financial statements [93] - There are no post-reporting period matters requiring shareholder attention [94]

证券代码：002399 证券简称：海普瑞 | --- | --- | --- | |-----------------------------|---------------------------------------|----------------| | | | 编号：2015-007 | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 天弘基金 董福焱 | | | | 时间 2015 年 10 月 30 日 14:00-15:00 | | | | 地点 高新中一道 19 号 A224 室 | | | 上市公司接待人 员姓名 | 步海华、黄克雨 | | | 投资者关系活动 主要内容介绍 | 了解公司生产经营情况 | | | | 附件清单（如有） 天弘基金调研会议纪要 | | | | 日期 2015 年 10 月 30 日 | | 深圳市海普瑞药业股份有限公司投资者关系活动记录表 k /o ...

证券代码：002399 证券简称：海普瑞 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------|-----------------| | | | 编号：2016-007 | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 国信证券：郭泓辰 | | | 人员姓名 | Shinhan BNP Paribas Asset Managemen Sectoral Asset Management BlackRock ： Matt Colvin | ：刘水茵 ：刘颖 | | | | | | 时间 2016 年 3 月 15 | | 日 09:00-10:30 | | | 地点 高新中一道 19 ...

证券代码：002399 证券简称：海普瑞 深圳市海普瑞药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------|----------------| | | | 编号：2016-002 | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 平安证券 叶寅 魏巍 | | | 人员姓名 | 融通基金 蒋秀蕾 中欧瑞博 汪洋 | | | 时间 2016 年 1 月 7 | 日 15:00-17:30 | | | | 地点 高新中一道 19 号 A218 室 | | | 上市公司接待人 员姓名 | 步海华、白琼 | | | 投资者关系活动 主要内容介绍 | 了解公司生产经营情况 | | | | 附件清单（如有） 平安证券等调研会议纪要 | | | | 日 ...

证券代码：002399 证券简称：海普瑞 深圳市海普瑞药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------------------|----------------| | | | 编号：2016-001 | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 华泰证券 肖汉山 | | | 时间 2016 年 1 月 7 | 日 10:00-12:00 | | | | 地点 高新中一道 19 号 A223 室 | | | | | | | 上市公司接待人 员姓名 | 步海华、白琼 | | | 投资者关系活动 主要内容介绍 | 了解公司生产经营情况 | | | | 附件清单（如有） 华泰证券调研会议纪要 | | | | 日期 2016 年 1 月 7 日 | | k ...

证券代码：002399 证券简称：海普瑞 深圳市海普瑞药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | 编号：2016-009 | | 投资者关系活动 | | ■特定对象调研 □分析师会议 | | 类别 | | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | □现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 华润云大基金：陈湛青；安信基金：许杰；恒大人寿：姚力伟；金信 | | 人员姓名 ...

证券代码：002399 证券简称：海普瑞 深圳市海普瑞药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------|----------------| | | | 编号：2016-004 | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 工银瑞信 庞文杰 | | | 人员姓名 | 长城证券 赵浩然 彭学龄 | | | 时间 2016 年 1 月 21 | | 日 09:30-11:30 | | | 地点 高新中一道 19 号 A224 室 | | | 上市公司接待人 员姓名 | 步海华、白琼 | | | 投资者关系活动 主要内容介绍 | 了解公司生产经营情况 | | | | 附件清单（如有） 工银瑞信等调研会议纪要 | | | | 日期 201 ...